Global peptide CDMO supply-demand balance Report Interpretation

Overview

This industry deep dive builds a global peptide CDMO supply-demand model. Bernstein expects a substantial long-term manufacturing opportunity led by GLP-1 therapies, rising dosage intensity and a widening non-GLP-1 peptide pipeline, while stressing that captive expansion by major drug sponsors could alter the balance for external CDMOs.

Core views

Bernstein’s central demand thesis is that peptide manufacturing demand should grow more rapidly and persistently than many investors expect. GLP-1 therapies remain the largest near-term contributor: the report forecasts the GLP-1 market to grow at a 29% CAGR through 2029, versus roughly 10% for non-GLP-1 peptides. However, the longer-term opportunity is not limited to incretins. The innovative peptide pipeline expanded from about 400 programs in 2020 to about 2,000 in 2025, a 38% five-year CAGR. While GLP-1 assets account for 58% of NDA-stage programs, they represent only 8–11% of preclinical through Phase 2 candidates, which Bernstein interprets as evidence that future innovation is increasingly concentrated in non-metabolic indications such as autoimmune disease and oncology. The report argues that dosage intensity is as important as patient growth. Dual agonists such as tirzepatide, triple agonists such as retatrutide and oral GLP-1 products are expected to gain share from first-generation mono-agonists over the coming decade. Bernstein estimates mono-agonists fall from roughly 50% of the market currently to below 15% by 2033, while dual and triple agonists together exceed 60% of the treated obesity market. Oral and chronic high-dose peptide therapies can require far more API per patient than injectable products: cited annual dosage ranges extend from roughly 7,000 mg for oral GLP-1 peptides to more than 70,000 mg for therapies such as icotrokinra in psoriasis. This shifts the manufacturing opportunity above what sales growth or patient counts alone imply. Using high-teens CAGR growth in treated patients and low-teens growth in average dosage per patient, Bernstein estimates net GLP-1 API demand in obesity rises from about 18 MT in 2026 to about 200 MT in 2033, a 31% CAGR. The report then converts patient-level demand into total manufacturing demand by applying a 1.6x multiplier for GLP-1 use in diabetes, cardiovascular disease, MASH and other metabolic indications; a 2x manufacturing-intensity multiplier for intermediates, synthesis losses and purification yields; and a further 1.5x supply-chain factor for fill-finish loss, inventory and safety stock. Adding non-GLP-1 branded therapies, biosimilars and generics, clinical peptides and cosmetic peptides lifts the 2026 estimate from 18 MT of net obesity GLP-1 API demand to about 202 MT of total peptide manufacturing demand. Bernstein projects total global demand reaches about 1.4kt by 2033. Supply is expanding rapidly across Chinese and global CDMOs and through captive pharmaceutical capacity. Bernstein estimates global installed synthesis capacity could reach roughly 500–600 kL by 2026, equivalent to about 383 MT of nameplate peptide output. It estimates output productivity of roughly 0.3–0.9 MT per 1 kL of installed capacity, with higher throughput at large commercial GLP-1 facilities than at clinical-stage or complex-modality plants. Applying an assumed 70% utilization rate and adjustments for cleaning, batch failures, changeovers and GMP approval timing reduces effective capacity to about 229 MT in 2026—around 40% below nameplate capacity. WuXi AppTec is described as the capacity leader, with more than 100 kL of SPPS capacity and plans for more than 130 kL by 2026; Asymchem targets 69 kL by 2026 from 45 kL. In Bernstein’s base case, Novo and Lilly retain a broadly similar share of industry capacity, allowing incremental demand to be split between captive plants and external CDMOs. Effective global supply consequently rises from about 229 MT in 2026 to about 1.4kt in 2033, broadly matching the demand forecast and supporting healthy utilization at leading suppliers. The key alternative scenario is aggressive sponsor insourcing: if Novo and Lilly build internal capabilities beyond disclosed projects to a scale greater than second-tier specialists such as Bachem and PolyPeptide, less commercial volume would remain available to outsourced manufacturers and industry utilization would come under pressure. Bernstein therefore views the allocation of production between captive and external networks—not end-market demand growth—as the decisive determinant of whether the sector experiences balanced growth or moderate oversupply.

Analysis framework

Bernstein starts with demand drivers, separating patient growth, dosage intensity and pipeline diversification. It converts obesity GLP-1 API demand into total manufacturing requirements using indication, process and supply-chain multipliers, then estimates global capacity from installed kL, company-specific output productivity, utilization and operating constraints. Finally, it compares supply and demand under a base case and an aggressive captive-expansion scenario.

Methodology notes

• Industry AnalysisSupply-demand framework

  Global peptide manufacturing supply-demand model

  The report forecasts peptide demand and effective manufacturing supply through 2033, then tests whether the market remains balanced under different captive-manufacturing assumptions.

• Industry AnalysisVolume-price decomposition

  Patient-volume and dosage-intensity demand decomposition

  Demand growth is built from treated-patient growth and rising peptide consumption per patient, rather than drug sales alone.

• Valuation methodsDCF (Discounted Cash Flow)

  Blended DCF, forward P/E and EV/EBITDA valuation for covered companies

  The disclosure appendix values the covered companies by weighting DCF, one-year-forward P/E and one-year-forward EV/EBITDA approaches equally.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Asymchem Laboratories Tianjin Co Ltd (06821.HK)

  Explicitly covered Chinese peptide CDMO positioned to benefit from peptide-capacity expansion.

  Strengths

  Targets 69 kL of SPPS capacity by 2026, up from 45 kL; Bernstein rates the shares Outperform.

  Comparison

  Smaller planned peptide capacity than WuXi AppTec’s more than 130 kL target for 2026.

  Risks

  Service-quality deterioration, higher integrated-project drop-out rates, geopolitical tension affecting global-ex-China share, and higher-than-estimated failure rates for new peptide modalities.

• WuXi AppTec Co Ltd (02359.HK)

  Explicitly covered diversified CDMO and peptide-capacity leader.

  Strengths

  More than 100 kL of SPPS capacity, planned to exceed 130 kL by 2026; Bernstein rates the shares Outperform.

  Comparison

  Described as the peptide-capacity leader among Chinese players.

  Risks

  Potential negative litigation-related updates regarding the 1260H list, high single-customer contribution and potential oversupply.

• Wuxi Biologics Cayman Inc (02269.HK)

  Explicitly covered CDMO exposed to broader outsourced biologics and related manufacturing demand.

  Strengths

  Bernstein cites potential upside from better-than-expected biologics and ADC performance or a large commercial order.

  Weaknesses

  Bernstein rates the shares Market-Perform.

  Risks

  Service-quality deterioration, higher integrated-project drop-out rates, geopolitical tension affecting global-ex-China share, and higher-than-estimated failure rates for ADC and BsAb modalities.

Key data

• Net obesity GLP-1 API demand~18 MT in 2026 to ~200 MT in 203331% CAGR in Bernstein’s estimate.
• Total global peptide manufacturing demand~202 MT in 2026 to ~1.4kt in 2033Includes GLP-1, non-GLP-1 therapies, biosimilars, clinical programs and other adjustments.
• Innovative peptide pipeline~400 programs in 2020 to ~2,000 in 202538% five-year CAGR.
• Global installed peptide capacity~500–600 kL in 2026Equivalent to roughly 383 MT of nameplate output in Bernstein’s conversion.
• Global effective peptide capacity~229 MT in 2026 to ~1.4kt in 2033Base case assumes Novo and Lilly maintain a broadly similar capacity share.
• Utilization assumption70%Used in converting nameplate to effective capacity.

Impact & implications

Bernstein sees a large long-term opportunity for scaled peptide manufacturers because manufacturing requirements rise with both patient volumes and dosage intensity. Its base case supports balanced supply-demand conditions, but external CDMO outcomes depend heavily on whether Novo and Lilly retain meaningful outsourcing rather than shift additional volume into captive facilities.

Risks

• More aggressive captive manufacturing expansion by Novo and Lilly could reduce outsourced commercial volume and pressure peptide CDMO utilization.
• Service-quality deterioration or higher project drop-out rates could weigh on covered CDMOs.
• Geopolitical tension could reduce global-ex-China market share for Chinese manufacturers.
• New treatment modalities, including peptides, ADCs and BsAbs, could have higher failure rates than Bernstein assumes.
• WuXi AppTec faces potential litigation-related updates concerning the 1260H list, customer concentration and possible sector oversupply.

What to watch

• Whether Novo and Lilly allocate incremental peptide production to captive plants or external CDMOs.
• The pace of GLP-1 adoption, the shift toward oral, dual- and triple-agonist therapies, and associated dosage intensity.
• Progression of the non-GLP-1 peptide pipeline into late-stage development and commercialization.
• Execution of announced capacity additions by Chinese and global peptide manufacturers.
• Industry utilization as effective supply approaches Bernstein’s projected demand trajectory.